Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vor Biopharma Inc (VOR)

Vor Biopharma Inc (VOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,537
  • Shares Outstanding, K 124,852
  • Annual Sales, $ 0 K
  • Annual Income, $ -116,914 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta -0.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings $-0.44 on 03/20/25
  • Next Earnings Date 05/15/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 223.01% ( -199.09%)
  • Historical Volatility 354.46%
  • IV Percentile 34%
  • IV Rank 13.25%
  • IV High 1,327.40% on 04/09/25
  • IV Low 54.29% on 05/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 111
  • Volume Avg (30-Day) 70
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 1,625
  • Open Int (30-Day) 2,032

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.20
  • Low Estimate -0.33
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1311 +32.04%
on 05/09/25
0.8496 -79.63%
on 04/23/25
-0.5269 (-75.27%)
since 04/11/25
3-Month
0.1311 +32.04%
on 05/09/25
1.5000 -88.46%
on 02/18/25
-1.1569 (-86.98%)
since 02/13/25
52-Week
0.1311 +32.04%
on 05/09/25
1.8700 -90.74%
on 05/16/24
-1.5269 (-89.82%)
since 05/13/24

Most Recent Stories

More News
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

VOR : 0.1663 (-3.59%)
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

VOR : 0.1663 (-3.59%)
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

VOR : 0.1663 (-3.59%)
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

VOR : 0.1663 (-3.59%)
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

VOR : 0.1663 (-3.59%)
Vor Bio Announces $55.6 Million Private Placement

VOR : 0.1663 (-3.59%)
Vor Bio Reports Promising Clinical Data for Trem-cel + Mylotarg in Acute Myeloid Leukemia Patients Post-Transplant

Vor Bio reports improved relapse-free survival and engraftment data from its Phase 1/2 VBP101 study in AML patients.Quiver AI SummaryVor Bio announced promising updates from its Phase 1/2 VBP101 study...

VOR : 0.1663 (-3.59%)
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

VOR : 0.1663 (-3.59%)
Vor Bio to Participate in the Stifel 2024 Healthcare Conference

VOR : 0.1663 (-3.59%)
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

VOR : 0.1663 (-3.59%)

Business Summary

Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 0.2023
2nd Resistance Point 0.1912
1st Resistance Point 0.1818
Last Price 0.1663
1st Support Level 0.1613
2nd Support Level 0.1502
3rd Support Level 0.1408

See More

52-Week High 1.8700
Fibonacci 61.8% 1.2057
Fibonacci 50% 1.0006
Fibonacci 38.2% 0.7954
Last Price 0.1663
52-Week Low 0.1311

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar